- Home
- ANL vs AVTX Comparison
ANL vs AVTX Comparison
Compare ANL & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- AVTX
- Stock Information
- Founded
- ANL 2004
- AVTX 2011
- Country
- ANL Cayman Islands
- AVTX United States
- Employees
- ANL N/A
- AVTX N/A
- Industry
- ANL
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- ANL
- AVTX Health Care
- Exchange
- ANL Nasdaq
- AVTX Nasdaq
- Market Cap
- ANL 56.0M
- AVTX 57.4M
- IPO Year
- ANL 2023
- AVTX 2015
- Fundamental
- Price
- ANL $1.55
- AVTX $4.89
- Analyst Decision
- ANL Hold
- AVTX Strong Buy
- Analyst Count
- ANL 1
- AVTX 7
- Target Price
- ANL N/A
- AVTX $31.00
- AVG Volume (30 Days)
- ANL 7.4K
- AVTX 82.2K
- Earning Date
- ANL 08-08-2025
- AVTX 08-11-2025
- Dividend Yield
- ANL N/A
- AVTX N/A
- EPS Growth
- ANL N/A
- AVTX N/A
- EPS
- ANL N/A
- AVTX N/A
- Revenue
- ANL N/A
- AVTX $441,000.00
- Revenue This Year
- ANL N/A
- AVTX N/A
- Revenue Next Year
- ANL N/A
- AVTX N/A
- P/E Ratio
- ANL N/A
- AVTX N/A
- Revenue Growth
- ANL N/A
- AVTX N/A
- 52 Week Low
- ANL $1.10
- AVTX $3.39
- 52 Week High
- ANL $4.10
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- ANL 47.53
- AVTX 54.89
- Support Level
- ANL $1.50
- AVTX $4.63
- Resistance Level
- ANL $1.60
- AVTX $5.02
- Average True Range (ATR)
- ANL 0.07
- AVTX 0.27
- MACD
- ANL 0.02
- AVTX 0.00
- Stochastic Oscillator
- ANL 60.42
- AVTX 72.73
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).